MetLife Investment Management’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $245K | Hold |
21,688
| – | – | ﹤0.01% | 2078 |
|
|
2025
Q1 | $250K | Buy |
21,688
+2,536
| +13% | +$29.3K | ﹤0.01% | 2081 |
|
|
2024
Q4 | $162K | Sell |
19,152
-3,137
| -14% | -$26.6K | ﹤0.01% | 2406 |
|
|
2024
Q3 | $258K | Hold |
22,289
| – | – | ﹤0.01% | 2154 |
|
|
2024
Q2 | $263K | Buy |
22,289
+5,513
| +33% | +$64.9K | ﹤0.01% | 2077 |
|
|
2024
Q1 | $199K | Hold |
16,776
| – | – | ﹤0.01% | 2205 |
|
|
2023
Q4 | $206K | Buy |
16,776
+4,281
| +34% | +$52.4K | ﹤0.01% | 2230 |
|
|
2023
Q3 | $120K | Hold |
12,495
| – | – | ﹤0.01% | 2486 |
|
|
2023
Q2 | $112K | Hold |
12,495
| – | – | ﹤0.01% | 2606 |
|
|
2023
Q1 | $98.2K | Hold |
12,495
| – | – | ﹤0.01% | 2561 |
|
|
2022
Q4 | $84.5K | Hold |
12,495
| – | – | ﹤0.01% | 2659 |
|
|
2022
Q3 | $181K | Hold |
12,495
| – | – | ﹤0.01% | 2359 |
|
|
2022
Q2 | $123K | Hold |
12,495
| – | – | ﹤0.01% | 2614 |
|
|
2022
Q1 | $184K | Buy |
12,495
+6,365
| +104% | +$93.8K | ﹤0.01% | 2396 |
|
|
2021
Q4 | $81.1K | Hold |
6,130
| – | – | ﹤0.01% | 2452 |
|
|
2021
Q3 | $107K | Hold |
6,130
| – | – | ﹤0.01% | 2416 |
|
|
2021
Q2 | $147K | Hold |
6,130
| – | – | ﹤0.01% | 2335 |
|
|
2021
Q1 | $157K | Sell |
6,130
-963
| -14% | -$24.7K | ﹤0.01% | 2172 |
|
|
2020
Q4 | $135K | Buy |
+7,093
| New | +$135K | ﹤0.01% | 2168 |
|
|
2019
Q3 | – | Sell |
-6,284
| Closed | -$139K | – | 2361 |
|
|
2019
Q2 | $139K | Buy |
+6,284
| New | +$139K | ﹤0.01% | 2228 |
|